CF PharmTech (02652.HK) has received voluntary undertakings from its core management to extend the lock-up period on their shareholdings by six months.

Zhito Finance APP News, Changfeng Pharmaceutical (02652.HK) announced that recently, the Company received voluntary undertakings from Dr. Liang Wenqing, co-founder, Chairman, Executive Director and Chief Executive Officer of the Company, and Dr. Li Li, co-founder, Executive Director and Chief Scientific Officer of the Company, based on their confidence in the Group's long-term development prospects and long-term value. Pursuant to the undertakings, the core management has voluntarily undertaken to further extend the lock-up period of the shares of the Company directly or indirectly beneficially owned by them by six months after the expiry of the original lock-up period. The extended lock-up period shall commence from October 8, 2026 and end on April 7, 2027 (both dates inclusive).